{"id":"caldiamide","rwe":[{"pmid":"24374816","year":"2014","title":"Classification of structurally related commercial contrast media by near infrared spectroscopy.","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"},{"pmid":"21263333","year":"2011","title":"Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study.","finding":"","journal":"Investigative radiology","studyType":"Clinical Study"},{"pmid":"20938346","year":"2011","title":"The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats.","finding":"","journal":"Investigative radiology","studyType":"Clinical Study"},{"pmid":"20938344","year":"2011","title":"Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis.","finding":"","journal":"Investigative radiology","studyType":"Clinical Study"},{"pmid":"19160079","year":"2009","title":"Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis.","finding":"","journal":"Acta radiologica (Stockholm, Sweden : 1987)","studyType":"Clinical Study"}],"tags":[{"label":"caldiamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["caldiamide"],"offLabel":[],"synonyms":["caldiamide"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"caldiamide","explanation":"Imagine your body's cells have locks on them, and caldiamide is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock open or closed, depending on the type of lock and the key's shape. This can affect how the cell works and responds to signals, but the exact details of how caldiamide works are still being studied.","oneSentence":"Caldiamide is a small molecule that works by interacting with a specific target, although its exact mechanism of action is currently unknown.","technicalDetail":"Caldiamide's mechanism of action is currently unknown, but it is believed to interact with a specific protein or receptor to produce its effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/467","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CALDIAMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:12:11.066852","biosimilars":[],"competitors":[],"genericName":"caldiamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"011024","UNII":"9229HWF92P","INN_ID":"6645","RXNORM":"1364944","UMLSCUI":"C0982050","ChEMBL_ID":"CHEMBL106971","PUBCHEM_CID":"60755"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":9,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2014 Mar","pmid":"24374816","title":"Classification of structurally related commercial contrast media by near infrared spectroscopy.","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"2011 May","pmid":"21263333","title":"Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study.","journal":"Investigative radiology"},{"date":"2011 Jan","pmid":"20938346","title":"The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats.","journal":"Investigative radiology"},{"date":"2011 Feb","pmid":"20938344","title":"Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis.","journal":"Investigative radiology"},{"date":"2009 Mar","pmid":"19160079","title":"Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis.","journal":"Acta radiologica (Stockholm, Sweden : 1987)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CALDIAMIDE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Caldiamide is a small molecule drug in the caldiamide class, but its target and mechanism of action are unknown. It is not clear if it has been approved by the FDA or if it is commercially available. There is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to understand its clinical applications and safety profile. As a result, it is difficult to provide a comprehensive summary of caldiamide's status and characteristics.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}